Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 21,094.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,711 shares of the medical research company’s stock after purchasing an additional 19,618 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Edwards Lifesciences were worth $1,884,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $34,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $34,000. Pingora Partners LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $38,000. Finally, Burkett Financial Services LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, CEO Bernard J. Zovighian acquired 580 shares of Edwards Lifesciences stock in a transaction dated Monday, May 6th. The shares were acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the sale, the director now owns 4,486 shares in the company, valued at $380,278.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,099 shares of company stock worth $7,003,553. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 31.3 %

Edwards Lifesciences stock traded down $27.25 during mid-day trading on Thursday, reaching $59.70. 45,810,477 shares of the company’s stock were exchanged, compared to its average volume of 3,697,431. Edwards Lifesciences Co. has a twelve month low of $58.94 and a twelve month high of $96.12. The company has a fifty day moving average of $89.12 and a 200-day moving average of $87.12. The company has a market cap of $35.98 billion, a P/E ratio of 26.20, a P/E/G ratio of 3.19 and a beta of 1.11. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the business earned $0.66 EPS. The company’s revenue was up 6.7% on a year-over-year basis. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th. Truist Financial cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $110.00 to $82.00 in a research note on Thursday. Stifel Nicolaus dropped their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday. Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $102.00 to $70.00 in a research note on Thursday. Finally, The Goldman Sachs Group began coverage on shares of Edwards Lifesciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $107.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $84.57.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.